Schering-Plough and Novartis enter into new respiratory alliance
Schering-Plough’s once daily inhaled corticosteroid mometasone, the active ingredient in Asmanex, and Novartis’ once daily beta2-agonist indacaterol (QAB149) will be combined in a single inhalation device. The combined
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.